This HTML5 document contains 106 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/AHFS/
n23http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00982/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n22http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00982/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n9http://www.rxlist.com/cgi/generic/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00982/identifier/wikipedia/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00982/identifier/pharmgkb/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00982/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00982/identifier/drugbank/
n24http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00982
rdf:type
n3:Drug
n3:description
Isotretinoin is a medication used for the treatment of severe acne. It is sometimes used in prevention of certain skin cancers. It is a retinoid, meaning it derives from vitamin A and is found in small quantities naturally in the body. Isotretinoin binds to and activates nuclear retinoic acid receptors (RAR), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.
n3:dosage
n7:271B48D9-363D-11E5-9242-09173F13E4C5 n7:271B48DA-363D-11E5-9242-09173F13E4C5 n7:271B48DB-363D-11E5-9242-09173F13E4C5 n7:271B48DC-363D-11E5-9242-09173F13E4C5 n7:271B48DD-363D-11E5-9242-09173F13E4C5 n7:271B48DE-363D-11E5-9242-09173F13E4C5 n7:271B48DF-363D-11E5-9242-09173F13E4C5 n7:271B48E0-363D-11E5-9242-09173F13E4C5 n7:271B48E1-363D-11E5-9242-09173F13E4C5 n7:271B48E2-363D-11E5-9242-09173F13E4C5 n7:271B48E3-363D-11E5-9242-09173F13E4C5 n7:271B48E4-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Berard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D: Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007 Feb;63(2):196-205. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17214828 # Holmes SC, Bankowska U, Mackie RM: The prescription of isotretinoin to women: is every precaution taken? Br J Dermatol. 1998 Mar;138(3):450-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9580798 # Amichai B, Shemer A, Grunwald MH: Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006 Apr;54(4):644-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16546586 # Seukeran DC, Cunliffe WJ: Acne vulgaris in the elderly: the response to low-dose isotretinoin. Br J Dermatol. 1998 Jul;139(1):99-101. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9764156 # Tirado Sanchez A, Leon Dorantes G: [Erectile dysfunction during isotretinoin therapy] Actas Urol Esp. 2005 Nov-Dec;29(10):974-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16447596
n3:group
approved
n3:halfLife
17-50 hours
n3:indication
For the treatment of severe recalcitrant nodular acne
owl:sameAs
n11:DB00982 n22:DB00982
dcterms:title
Isotretinoin
adms:identifier
n15:Isotretinoin n16:PA450128 n18:0004-0155-49 n19:D00348 n20:6067 n21:DB00982
n3:mechanismOfAction
Isotretinoin noticeably reduces the production of sebum and shrinks the sebaceous glands. It stabilises keratinization and prevents comedones from forming. It also reduces inflammation in moderate-severe inflammatory acne. The exact mechanism of action is unknown, however it is known that it alters DNA transcription.
n3:packager
n23:271B48C8-363D-11E5-9242-09173F13E4C5 n23:271B48C2-363D-11E5-9242-09173F13E4C5 n23:271B48C3-363D-11E5-9242-09173F13E4C5 n23:271B48C6-363D-11E5-9242-09173F13E4C5 n23:271B48C7-363D-11E5-9242-09173F13E4C5 n23:271B48C4-363D-11E5-9242-09173F13E4C5 n23:271B48C5-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Isotretinoin and its metabolites are further metabolized into conjugates, which are then excreted in urine and feces. The metabolites of isotretinoin and any conjugates are ultimately excreted in the feces and urine in relatively equal amounts (total of 65% to 83%).
n3:synonym
Neovitamin a acid Claravis Isotretinoino 13-RA Isotretinoine 13-cis-Vitamin a acid Isotretinoinum (7e,9e,11e,13Z)-Retinoic acid 13-cis-Retinoic acid Amnesteem Accutane cis-RA Isotretinoina
n3:toxicity
Isotretinoin is teratogenic. It also causes mucocutaneous side effects suck as cheilitis, dry skin, and dry eyes.
n12:hasAHFSCode
n13:84-92-00
n3:foodInteraction
Avoid alcohol. Take with a full glass of water Do not take supplements containing Vitamin A. Take with high-fat meal to increase absorption.
n3:proteinBinding
99.9%
n3:synthesisReference
Ashok Kumar, Dharmendra Singh, Ganesh Devidas Mahale, Ragnesh Kumar Rana, Mahesh Kharade, "PROCESS FOR PREPARATION OF HIGHLY PURE ISOTRETINOIN." U.S. Patent US20080207946, issued August 28, 2008.
foaf:page
n6:isotretinoin.html n9:isotret.htm
n3:IUPAC-Name
n4:271B48E9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B48EF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B48EE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B48EB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B48EC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B48ED-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B48E7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B48FE-363D-11E5-9242-09173F13E4C5 n4:271B48E5-363D-11E5-9242-09173F13E4C5 n4:271B48E8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B48E6-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n24:D10AD04 n24:D10BA01
n3:H-Bond-Acceptor-Count
n4:271B48F5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B48F6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B48F0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B48F1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B48F3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B48F2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B48F4-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
4759-48-2
n3:category
n3:clearance
* 96 +/- 6.27 L/hr [severe recalcitrant nodular acne pediatric Patients, 12 to 15 Years]
n3:containedIn
n17:271B48D8-363D-11E5-9242-09173F13E4C5 n17:271B48D2-363D-11E5-9242-09173F13E4C5 n17:271B48D3-363D-11E5-9242-09173F13E4C5 n17:271B48D0-363D-11E5-9242-09173F13E4C5 n17:271B48D1-363D-11E5-9242-09173F13E4C5 n17:271B48D6-363D-11E5-9242-09173F13E4C5 n17:271B48D7-363D-11E5-9242-09173F13E4C5 n17:271B48D4-363D-11E5-9242-09173F13E4C5 n17:271B48D5-363D-11E5-9242-09173F13E4C5 n17:271B48CA-363D-11E5-9242-09173F13E4C5 n17:271B48CB-363D-11E5-9242-09173F13E4C5 n17:271B48C9-363D-11E5-9242-09173F13E4C5 n17:271B48CE-363D-11E5-9242-09173F13E4C5 n17:271B48CF-363D-11E5-9242-09173F13E4C5 n17:271B48CC-363D-11E5-9242-09173F13E4C5 n17:271B48CD-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B48FA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B48FC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B48FD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B48F9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B48F8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B48FB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B48EA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B48F7-363D-11E5-9242-09173F13E4C5